Patents by Inventor Jennifer Hope Richardson

Jennifer Hope Richardson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CD71 ACTIVATABLE ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF
    Publication number: 20240115724
    Abstract: The invention relates generally to conjugated activatable antibodies that bind CD71 in their active form and methods of making and using these anti-CD71 conjugated activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: May 19, 2023
    Publication date: April 11, 2024
    Inventors: Shweta SINGH, Jennifer Hope RICHARDSON, Laura Patterson SERWER, Jonathan Alexander TERRETT, Susan E. MORGAN-LAPPE, Tracy HENRIQUES, Sherry L. RALSTON, Marvin Robert LEANNA, Ilaria BADAGNANI
  • Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
    Patent number: 11802158
    Abstract: The invention relates generally to antibodies, activatable antibodies, multispecific antibodies, and multispecific activatable antibodies that specifically bind to at least CD3, as well as to methods of making and using these antibodies, activatable antibodies, multispecific antibodies, and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: October 31, 2023
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: Bryan Allen Irving, Sherry Lynn La Porte, Jason Gary Sagert, Daniel Robert Hostetter, Olivia Jennifer Razo, Clayton William White, Jennifer Hope Richardson
  • ANTI-CD71 ACTIVATABLE ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF
    Publication number: 20210145978
    Abstract: The invention relates generally to conjugated activatable antibodies that bind CD71 in their active form and methods of making and using these anti-CD71 conjugated activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: November 25, 2020
    Publication date: May 20, 2021
    Inventors: Shweta Singh, Jennifer Hope Richardson, Laura Patterson Serwer, Jonathan Alexander Terret, Susan E. Morgan-Lappe, Tracy Henriques, Sherry L. Ralston, Marvin Robert Leanna, Ilari Badagnani, Sahana Bose
  • BISPECIFIC ANTI-CD3 ANTIBODIES, BISPECIFIC ACTIVATABLE ANTI-CD3 ANTIBODIES, AND METHODS OF USING THE SAME
    Publication number: 20210047406
    Abstract: The invention relates generally to antibodies, activatable antibodies, multispecific antibodies, and multispecific activatable antibodies that specifically bind to at least CD3, as well as to methods of making and using these antibodies, activatable antibodies, multispecific antibodies, and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: April 24, 2020
    Publication date: February 18, 2021
    Inventors: Bryan Allen IRVING, Sherry Lynn LA PORTE, Jason Gary SAGERT, Daniel Robert HOSTETTER, Olivia Jennifer RAZO, Clayton William WHITE, Jennifer Hope RICHARDSON
  • Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
    Patent number: 10669337
    Abstract: The invention relates generally to antibodies, activatable antibodies, multispecific antibodies, and multispecific activatable antibodies that specifically bind to at least CD3, as well as to methods of making and using these antibodies, activatable antibodies, multispecific antibodies, and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: June 2, 2020
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Bryan Allen Irving, Sherry Lynn La Porte, Jason Gary Sagert, Daniel Robert Hostetter, Olivia Jennifer Razo, Clayton William White, Jennifer Hope Richardson
  • ANTI-CD71 ACTIVATABLE ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF
    Publication number: 20190111150
    Abstract: The invention relates generally to conjugated activatable antibodies that bind CD71 in their active form and methods of making and using these anti-CD71 conjugated activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: October 12, 2018
    Publication date: April 18, 2019
    Inventors: Shweta SINGH, Jennifer Hope RICHARDSON, Laura Patterson SERWER, Jonathan Alexander TERRETT, Susan E. MORGAN-LAPPE, Tracy HENRIQUES, Sherry L. RALSTON, Marvin Robert LEANNA, Ilaria BADAGNANI, Sahana BOSE
  • ANTI-CD3 ANTIBODIES, ACTIVATABLE ANTI-CD3 ANTIBODIES, MULTISPECIFIC ANTI-CD3 ANTIBODIES, MULTISPECIFIC ACTIVATABLE ANTI-CD3 ANTIBODIES, AND METHODS OF USING THE SAME
    Publication number: 20160194399
    Abstract: The invention relates generally to antibodies, activatable antibodies, multispecific antibodies, and multispecific activatable antibodies that specifically bind to at least CD3, as well as to methods of making and using these antibodies, activatable antibodies, multispecific antibodies, and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: July 24, 2015
    Publication date: July 7, 2016
    Inventors: Bryan Allen Irving, Sherry Lynn La Porte, Jason Gary Sagert, Daniel Robert Hostetter, Olivia Jennifer Razo, Clayton William White, Jennifer Hope Richardson